Gen-Probe, Inc.

• Hologic's Wholly Illogical Merger

  By j.a. graham - May 7, 2012 | Tickers: GPRO, HOLX, QGEN

   

  Hologic (NASDAQ: HOLX) specializes in women’s health and operates in four business segments:

  • Breast Health   31%
  • Diagnostics     32%
  • GYN Surgical    17%
  • Skeletal Health  3%

  The company was a pioneer in digital mammography taking on the big conglomerates like GE and Siemens AG who had much larger and better-established radiology divisions. Hologic’s early growth was astronomic. 

  Part of that growth was through business mergers and acquisitions. They made six more »

• Avoid this Diagnostics Company

  By Meena Krishnamsetty - May 1, 2012 | Tickers: CPTS, GPRO, HOLX, NVS, QGEN

  This week Hologic (NASDAQ: HOLX) announced it would acquire Gen-Probe (NASDAQ: GPRO) for $3.7 billion or $82.75/share, a 20% premium based on last Friday’s close, representing ~6.0x CY 2012 revenue and ~23.0x CY 2012EBITDA, pre-synergies. The transaction financing will be all-cash and is expected to close later this year. The companies are projecting $75 million in synergies over three years, making the deal theoretically more »

• Johnson & Johnson Updates on the State of the Healthcare Market

  By Lee Samaha - April 18, 2012 | Tickers: ACT, GPRO, JNJ, MJN, PFE

  Johnson & Johnson (NYSE: JNJ) gave results recently and underperformed the broader market on what was a strong up day. There wasn't anything inherently wrong in the numbers, but there wasn't anything sexy about them either. Revenues were slightly down, with a negative currency effect of 1.2% not helping matters. However, top line growth is not the key for JNJ.

  JNJ’s attraction is of the kind that more »